ANG-3777 Phase 2 CSA-AKI Results Call Transcript
Hello and welcome to the Angion data call. (Operator Instructions) As a reminder, this conference is being recorded.
It's now my pleasure to turn the call over to David Miller. Please go ahead.
Thank you, operator.
Good afternoon, and thank you for joining us on our conference call to discuss the results of our Phase two trial of ANG-3777 in patients undergoing cardiac surgery involving cardiopulmonary bypass, who are at risk for developing acute kidney injury, otherwise known as CSA-AKI.
On the call with me today is Dr. Jay Venkatesan, Angion's President and CEO. After the closing bell, we issued a press release with topline data from this Phase 2 study. The release is accessible on the investors section of our website at www.angion.com. A recording of this call will be available in the investors section of our website under events and presentations shortly after the call concludes.
As a reminder, before we begin, the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
